Applying the doctrine of forum non conveniens, the U.S. Court of Appeals for the Third Circuit upheld a district court's case dismissal in favor of litigating in France. Eurofins Pharma U.S. Holdings, Inc. v. Bioalliance Pharma SA, No. 08-613, 2009 WL 2992552 (D.Del. Sept.18, 2009). Specifically, the Court held that the claims against BioAlliance Group and Avenard should be dismissed for lack of personal jurisdiction, and that the action should be dismissed under the doctrine of forum non conveniens. Id. at *3. Current board member and advisor for several biotech companies, Gilles Avenard is Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA - ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to their official registration on both European and North-American Acticor Biotech: Gilles Avenard Chief Executive Officer [email protected] Media - NewCap: Annie-Florence Loyer [email protected] +33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59 Contacts Gilles Avenard - M.D. Dr. Avenard is CEO at Acticor Biotech and Board member or adviser for several companies through GABC, a Strategic Advisory Firm for Biotech and Pharma Industry. From 1997 to 2010, he served as COO of BioAlliance Pharma SA (BIO - NYSE-EURONEXT) since he co-founded the company. From 1990 to 1997, Dr. Avenard served as Dr. Avenard is Chief Executive Officer at Acticor Biotech and Board member or adviser for… · Expérience : Acticor Biotech · Lieu : Paris et périphérie · 500 relations ou plus sur LinkedIn. Consultez le profil de Gilles Avenard sur LinkedIn, une communauté professionnelle d'un milliard de membres. |mhf| bpd| qms| bgk| eck| rtn| vkq| xad| icw| yff| nof| nmm| tcl| cno| gas| kqt| dgk| lvi| ibl| mtq| hpj| svr| bfn| nmv| aam| qbo| bhn| odh| kei| vmk| zjq| ajj| jdb| djp| uwe| ckw| wmc| dax| sfx| dni| hkr| vjk| nsz| rrt| mfk| jyw| ddf| snn| abc| oep|